Combination Immunotherapy and Chemotherapy Regimens in NSCLC: Clinical Practice Recommendations for Oncology Nurses

Get up to date on the nurse’s critical role in caring for patients receiving chemoimmunotherapy for NSCLC with downloadable slides and an on-demand webcast from a workshop series, along with a decision support tool providing expert recommendations on managing key toxicities from combination regimens.

Share

Program Content

Activities

Combo IO-CT for Nurses
Combination Immunotherapy and Chemotherapy Regimens in NSCLC: Clinical Practice Recommendations for Oncology Nurses
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 10, 2023

Activities

IO-CT in NSCLC for Nurses
Combination Immunotherapy and Chemotherapy Regimens in NSCLC: Clinical Practice Recommendations for Oncology Nurses
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 05, 2023

Expires: October 04, 2024

Activities

Assessing AEs With Chemoimmunotherapy in NSCLC
Assessing Adverse Events in Patients Receiving Chemoimmunotherapy Regimens for Non-Small-Cell Lung Cancer
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: October 19, 2023

Expires: December 14, 2024

Faculty

cover img faculity

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

cover img faculity

Matthew Gubens, MD, MS, FASCO

Professor of Medicine
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

cover img faculity

Rasheda Persinger, MSN, AGNP-C, AOCNP

Medical Oncology Lead Nurse Practitioner
Sidney Kimmel Cancer Center Sibley Memorial Hospital
Johns Hopkins System
Washington, DC

Provided by

ProCE Banner

Provided by Clinical Care Options

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc